Hematocrit on Testosterone: Erythrocytosis Explained

Hematocrit is the number that most often forces a change in a testosterone protocol, and it is also the number surrounded by the most confident misinformation. It gets dismissed as meaningless, it gets treated as an emergency, and it gets managed with a blood donation schedule that in some cases makes the underlying situation worse. The physiology is well understood and worth getting right.

Why Testosterone Raises Red Cell Mass

The dominant mechanism is iron, not erythropoietin. Testosterone suppresses hepcidin, the hepatic peptide that controls iron export from enterocytes and macrophages by degrading the iron exporter ferroportin. Lower hepcidin means more ferroportin, which means more dietary iron absorbed and more recycled iron released from macrophages, which means more substrate available to the bone marrow for haemoglobin synthesis.

Alongside this, testosterone appears to reset the relationship between haemoglobin and erythropoietin, so that EPO levels which would previously have been appropriate for a given haemoglobin now support a higher one. The set point moves. There is also evidence for direct stimulation of erythroid progenitors. The net result across these routes is a predictable, dose-related rise in red cell mass, which was recognised long before testosterone was used for hypogonadism, when androgens were a treatment for aplastic anaemia.

Ohlander and colleagues reviewed erythrocytosis following testosterone therapy and highlighted the consistent finding that formulation matters considerably. Injectable testosterone, particularly at longer intervals with higher peak concentrations, produces substantially more erythrocytosis than transdermal gels. Peak concentration appears to drive the effect more than average exposure, which is the mechanistic argument behind more frequent, smaller injections.

What the Risk Evidence Actually Shows

Here honesty is required, because this is a place where both the alarmist and the dismissive camps overstate their case.

The concern is that raised haematocrit increases blood viscosity, and viscosity rises non-linearly at the upper end, so that the increment from 52 to 56 percent matters more than the increment from 44 to 48. Higher viscosity plausibly promotes thrombosis. In polycythaemia vera, a myeloproliferative disease, controlling haematocrit demonstrably reduces thrombotic events, which establishes the principle in at least one setting.

Whether the same applies to testosterone-induced erythrocytosis is less settled. Observational data associate higher haematocrit on therapy with more venous thromboembolism and cardiovascular events. Fernández-Balsells and colleagues, in a systematic review of adverse effects of testosterone therapy, found erythrocytosis to be the most consistently observed adverse outcome, occurring several times more often than with placebo. What has been harder to demonstrate is a randomised trial showing that treating the erythrocytosis reduces events. The TRAVERSE trial, reported by Lincoff and colleagues, examined cardiovascular safety of testosterone replacement in men with hypogonadism and cardiovascular risk and did not find an excess of major adverse cardiac events, though it did note higher rates of certain outcomes including pulmonary embolism.

The reasonable reading is that this is a real signal of uncertain magnitude. It is not nothing, and it is not established as a major driver of events at replacement doses. Supraphysiological doses sustained for years are a different exposure entirely and are not what these trials studied.

The Contributors People Miss

Attributing a rising haematocrit entirely to testosterone is a common error, and it leads to dose reductions that do not fix the problem.

The sleep apnoea link deserves emphasis because it is bidirectional and under-recognised. Hoyos and colleagues studied testosterone therapy in obese men with severe obstructive sleep apnoea and observed worsening of breathing measures, and Killick and colleagues examined effects on ventilatory responses. A man whose haematocrit climbs on therapy, who snores, who is tired despite adequate sleep, and who carries substantial neck mass should be screened for sleep apnoea before anyone reaches for a phlebotomy needle.

How It Is Managed Clinically

This is a physician’s decision and it depends on the absolute value, the trend, symptoms, and thrombotic risk factors. The general clinical hierarchy is worth understanding rather than copying.

First, confirm the result on a properly hydrated, rested draw, because a substantial fraction of alarming values do not reproduce. Second, identify and treat contributors, above all sleep apnoea and smoking. Third, adjust the therapy itself: reducing dose, shortening the interval between injections to lower peak concentrations, or switching from injectable to transdermal delivery all reduce erythrocytosis, and the Endocrine Society guideline authored by Bhasin and colleagues addresses monitoring and dose adjustment for exactly this reason.

Therapeutic phlebotomy comes after those steps, not before, and it is not consequence-free. Repeated venesection depletes iron, and iron-deficient erythropoiesis produces microcytic red cells and can leave people symptomatic with fatigue and reduced exercise capacity while the haematocrit looks acceptable. There is also a plausible argument that iron depletion increases platelet counts. Routine scheduled blood donation as self-management, without monitoring ferritin, is a pattern that causes real problems and is common in this community.

Monitoring intervals in guideline documents typically involve checking haematocrit at baseline, at three to six months after starting or changing dose, and annually thereafter, with more frequent checks if values are rising.

The Framing

Under the Tony Huge Laws of Biochemistry Physics, this is a textbook self-regulating system problem. You push the erythropoietic axis with an androgen; the body does not push back in a way that protects you, because there is no negative feedback loop that caps haematocrit at a safe number. The governor you are relying on does not exist. That is precisely why external monitoring is the substitute, and why a number that drifts upward unwatched for two years is the failure mode that actually hurts people.

The related markers worth watching alongside it are ferritin, to detect the iron depletion that phlebotomy causes, and blood pressure, which frequently rises in parallel and compounds the vascular risk.

Where This Fits in the Bigger Picture

Monitoring is the part of enhancement that nobody posts about, and it is the part that decides how long you get to keep doing this. Testing gives you a feedback loop; without one you are guessing with your organs. Start with the Enhanced Athlete Protocol bloodwork guide, then work through the full protocol hub to see how testing, training, nutrition and recovery connect. If you are early in this, the beginners page is the right entry point.

See the hormone optimization pillar for how formulation and dosing interval interact with side effect profiles.

Frequently Asked Questions

Why does testosterone raise hematocrit?

Testosterone suppresses hepcidin, the liver hormone that restricts iron availability, which increases the iron supply to the bone marrow for red cell production. It also appears to shift the set point of the relationship between haemoglobin and erythropoietin, and may stimulate erythroid progenitor cells directly. The result is a dose-related increase in red cell mass that is more pronounced with injectable preparations than transdermal ones.

Is a high hematocrit on TRT dangerous?

Elevated haematocrit increases blood viscosity, and observational studies associate it with a higher rate of thrombotic events. However, randomised trial evidence establishing that treating testosterone-induced erythrocytosis reduces events is limited. It is best regarded as a real but incompletely quantified risk that warrants monitoring and clinical management rather than either panic or dismissal.

Should I donate blood to lower my hematocrit?

Therapeutic phlebotomy is one option, but clinicians generally look first at confirming the reading in a hydrated state, treating contributors such as sleep apnoea or smoking, and adjusting dose or formulation. Repeated blood removal depletes iron, which can cause fatigue and reduced performance even when the haematocrit looks acceptable, so it should be done under medical supervision with ferritin monitored rather than on a self-imposed schedule.

Does injection frequency affect hematocrit?

Peak testosterone concentration appears to drive erythrocytosis more than average exposure, which is the reasoning behind more frequent, smaller injections producing smaller rises than large infrequent doses. Transdermal preparations, which avoid sharp peaks altogether, are consistently associated with the lowest rates of erythrocytosis in published comparisons.

What else raises hematocrit besides testosterone?

Obstructive sleep apnoea, smoking, living at altitude, chronic lung disease, dehydration and plasma volume contraction from diuretics or aggressive dieting all raise it. Rarely, a primary bone marrow disorder such as polycythaemia vera is responsible. Because several of these are common in trained men and easy to overlook, they should be considered before the rise is attributed solely to therapy.